Felicetto Ferrara

Also affiliated with Fatebenefratelli Hospital

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10”.

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10

Journal of Clinical Oncology(2009)10.1200/jco.2008.20.6490

N/A

0.786DataRank · unranked

188 citations

Marco Vignetti, Stefan Suciu, Roberto Stasi, Maria-Concetta Petti, Giovanna Meloni +15 more

Long-term survival can be achieved in a significant fraction of older patients with core binding factor acute myeloid leukemia treated with intensive chemotherapy

Haematologica(2024)10.3324/haematol.2024.285448

N/A

0.241DataRank · unranked

4 citations

Erika Borlenghi, Mark R. Litzow, John C. Byrd, Cristina Papayannidis, Cristina Tecchio +34 more